Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Bossuyt

Showing results (111-120 of 134) with videos related to

Pageof 14
Sort By:
Lancet (London, England)|November 4, 2017
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trialJean-Frederic Colombel, Remo Panaccione, Peter Bossuyt, et al.
Inflammatory Bowel Diseases|July 12, 2017
Long-term Outcomes with Anti-TNF Therapy and Accelerated Step-up in the Prospective Pediatric Belgian Crohn's Disease Registry (BELCRO)Lucas Wauters, Françoise Smets, Elisabeth De Greef, et al.
Journal of Crohn'S & Colitis|February 8, 2020
Quality of Care Standards in Inflammatory Bowel Diseases: a European Crohn's and Colitis Organisation [ECCO] Position PaperGionata Fiorino, Theodore Lytras, Lisa Younge, et al.
The New England Journal of Medicine|July 17, 2024
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's DiseaseLaurent Peyrin-Biroulet, J Casey Chapman, Jean-Frederic Colombel, et al.
Alimentary Pharmacology & Therapeutics|November 7, 2019
Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE studyAnnick Moens, C Janneke van der Woude, Mette Julsgaard, et al.
JAMA|July 22, 2024
Risankizumab for Ulcerative Colitis: Two Randomized Clinical TrialsEdouard Louis, Stefan Schreiber, Remo Panaccione, et al.
Lancet (London, England)|June 1, 2022
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialMarc Ferrante, Remo Panaccione, Filip Baert, et al.
BMJ Open Gastroenterology|February 9, 2024
Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trialVipul Jairath, Guangyong Zou, Zhongya Wang, et al.
Lancet (London, England)|June 1, 2022
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trialsGeert D'Haens, Remo Panaccione, Filip Baert, et al.
United European Gastroenterology Journal|October 14, 2025
International Survey of Gastroenterologists on Managing Inflammatory Bowel Disease During Pregnancy and Lactation: Current State and the Necessity for ImprovementsMaría José Casanova, Javier P Gisbert, Aurelien Amiot, et al.
Pageof 14

Showing results (111-120 of 134) with videos related to

Sort By:
Pageof 14
Lancet (London, England)|November 4, 2017
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trialJean-Frederic Colombel, Remo Panaccione, Peter Bossuyt, et al.
Inflammatory Bowel Diseases|July 12, 2017
Long-term Outcomes with Anti-TNF Therapy and Accelerated Step-up in the Prospective Pediatric Belgian Crohn's Disease Registry (BELCRO)Lucas Wauters, Françoise Smets, Elisabeth De Greef, et al.
Journal of Crohn'S & Colitis|February 8, 2020
Quality of Care Standards in Inflammatory Bowel Diseases: a European Crohn's and Colitis Organisation [ECCO] Position PaperGionata Fiorino, Theodore Lytras, Lisa Younge, et al.
The New England Journal of Medicine|July 17, 2024
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's DiseaseLaurent Peyrin-Biroulet, J Casey Chapman, Jean-Frederic Colombel, et al.
Alimentary Pharmacology & Therapeutics|November 7, 2019
Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE studyAnnick Moens, C Janneke van der Woude, Mette Julsgaard, et al.
JAMA|July 22, 2024
Risankizumab for Ulcerative Colitis: Two Randomized Clinical TrialsEdouard Louis, Stefan Schreiber, Remo Panaccione, et al.
Lancet (London, England)|June 1, 2022
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialMarc Ferrante, Remo Panaccione, Filip Baert, et al.
BMJ Open Gastroenterology|February 9, 2024
Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trialVipul Jairath, Guangyong Zou, Zhongya Wang, et al.
Lancet (London, England)|June 1, 2022
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trialsGeert D'Haens, Remo Panaccione, Filip Baert, et al.
United European Gastroenterology Journal|October 14, 2025
International Survey of Gastroenterologists on Managing Inflammatory Bowel Disease During Pregnancy and Lactation: Current State and the Necessity for ImprovementsMaría José Casanova, Javier P Gisbert, Aurelien Amiot, et al.
Pageof 14